₹236.38
−7.42%NSE close, 16 Nov 2026
+10.05%
Viyash Scientific is a small cap company in the Healthcare sector, listed on NSE under the symbol VIYASH. At ₹236.38 a share, the market values the whole company at ₹10,439 crore.
In FY26, it reported sales of ₹3,420 crore and a net profit of ₹177 crore, an operating margin of 19.1%. Over the last three years, sales grew 34.0% a year.
The market values the company at 44.9 times its profit over the last twelve months and 3.30 times its book value; its return on equity is 7.3% and its borrowings are 0.17 times its equity.
Promoters hold 49.24% of the shares. Foreign institutions hold 2.60%, and domestic institutions, mutual funds among them, 8.30%.
Over the past year the share price has risen 9.2%, and it is 20.7% below its 52-week high.
Companies of a similar size in the same sector include Concord Biotech, Metropolis Healthcare, Akums Drugs and Pharmaceuticals and Park Medi World.
₹ crore. Consolidated figures.
The same sector (Healthcare), nearest in size.
| Company | Price | Market cap | P/E | ROE | Sales growth | 1Y |
|---|---|---|---|---|---|---|
| Viyash Scientific | ₹236.38 | ₹10,439 cr | 44.9 | 7.3% | +133.00% | +9.21% |
| Concord Biotech | ₹581.00 | ₹12,156 cr | 43.0 | 13.6% | +25.10% | −17.67% |
| Metropolis Healthcare | ₹574.15 | ₹11,907 cr | 53.1 | 13.7% | +15.80% | +14.50% |
| Akums Drugs and Pharmaceuticals | ₹722.20 | ₹11,367 cr | 31.2 | 10.4% | +31.90% | +56.88% |
| Park Medi World | ₹245.03 | ₹10,584 cr | 41.3 |
Link of Recording
Press Release for Q2 FY27
The financial results for the period ended September 30, 2026.
Allotment of 228408 Shares.
Schedule of meet
The update on Incorporation of step down wholly owned Subsidiary in vietnam.
Written from the company's filings with NSE and the exchanges' daily prices. For information only, not a recommendation to buy, sell or hold any security.
| Mar 2026 |
|---|
| Jun 2026 |
|---|
| Sep 2026 |
|---|
| Sales | 329 | 361 | 390 | 369 | 391 | 402 | 441 | 424 | 858 | 920 | 946 | 988 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Expenses | 307 | 329 | 348 | 330 | 356 | 355 | 389 | 368 | 683 | 736 | 768 | 823 |
| Operating profit | 22.3 | 32.3 | 42.0 | 39.1 | 34.5 | 46.2 | 52.2 | 55.7 | 176 | 184 | 178 | 165 |
| Operating margin | 6.8% | 8.9% | 10.8% | 10.6% | 8.8% | 11.5% | 11.8% | 13.1% | 20.5% | 20.0% | 18.8% | 16.7% |
| Other income | 4.5 | 4.0 | 2.7 | 4.5 | 5.8 | 1.7 | 3.9 | 2.2 | 14.0 | 15.9 | 8.3 | 11.8 |
| Interest | 12.6 | 12.4 | 16.4 | 14.3 | 15.0 | 15.1 | 14.2 | 13.5 | 16.8 | 14.5 | 12.5 | 13.7 |
| Depreciation | 15.5 | 16.5 | 16.3 | 17.1 | 17.0 | 16.1 | 15.1 | 15.5 | 58.5 | 60.4 | 61.8 | 45.3 |
| Profit before tax | 1.5 | 2.6 | 12.0 | 7.9 | 8.1 | 16.3 | 25.5 | 27.2 | 73.1 | 125 | 112 | 118 |
| Tax | −9.2 | 1.4 | 2.9 | 1.6 | 1.6 | 5.9 | 8.0 | 7.6 | 24.6 | 58.9 | 33.1 | 33.0 |
| Net profit | 8.3 | −0.9 | 6.5 | 6.3 | 3.4 | 9.3 | 14.3 | 14.7 | 38.4 | 52.1 | 65.9 | 76.2 |
| EPS (₹) | 0.33 | -0.04 | 0.26 | 0.10 | 0.14 | 0.37 | 0.57 | 0.59 | 0.89 | 1.20 | 1.51 | 1.74 |
₹ crore, financial years to March.
| Line | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| Sales | 1,039 | 1,179 | 1,362 | 1,413 | 1,421 | 1,370 | 1,551 | 3,420 |
| Expenses | 914 | 1,009 | 1,150 | 1,303 | 1,409 | 1,308 | 1,390 | 2,768 |
| Operating profit | 125 | 170 | 212 | 109 | 12.0 | 61.4 | 162 | 653 |
| Operating margin | 12.0% | 14.4% | 15.6% | 7.7% | 0.8% | 4.5% | 10.4% | 19.1% |
| Other income | 8.7 | 10.1 | 8.4 | 10.9 | 6.4 | 11.0 | 14.7 | 43.6 |
| Interest | 32.8 | 35.7 | 24.4 | 15.8 | 35.5 | 48.1 | 60.8 | 69.2 |
| Depreciation | 41.9 | 50.6 | 50.6 | 51.1 | 54.3 | 61.5 | 66.5 | 234 |
| Profit before tax | 58.9 | 94.1 | 137 | 53.4 | −136 | −54.6 | 44.3 | 349 |
| Tax | 2.0 | 12.0 | 32.2 | 8.3 | −15.2 | −25.0 | 12.1 | 124 |
| Net profit | 48.7 | 69.9 | 95.4 | 41.3 | −120 | −35.9 | 21.9 | 177 |
| EPS (₹) | 2.00 | 2.87 | 3.87 | 1.67 | -4.85 | -1.45 | 0.88 | 4.09 |
₹ crore, at each year's end and the latest half year.
| Line | FY23 | FY24 | FY25 | FY26 | Sep 2026 |
|---|---|---|---|---|---|
| Shareholders’ equity | 699 | 657 | 704 | 2,911 | 3,165 |
| Borrowings | 398 | 451 | 446 | 436 | 531 |
| Total liabilities | 780 | 827 | 832 | 1,514 | 1,738 |
| Fixed assets | 301 | 249 | 232 | 1,138 | 1,167 |
| Investments | 0.0 | 0.9 | 0.0 | 0.0 | 0.0 |
| Cash and equivalents | 41.6 | 64.8 | 62.7 | 256 | 493 |
| Total assets | 1,529 | 1,540 | 1,602 | 4,628 | 5,131 |
₹ crore, by financial year, and the latest half year.
| Line | FY22 | FY25 | FY26 | 6M to Sep 2026 |
|---|---|---|---|---|
| From operations | 30.6 | 83.4 | 323 | 183 |
| From investing | −94.1 | −24.8 | −84.1 | −55.3 |
| From financing | 67.3 | −60.7 | −123 | 109 |
| Spent on fixed assets | −32.5 | −39.1 | −135 | −67.4 |
| Free cash flow | −1.9 | 44.3 | 188 | 115 |
Margins, returns, debt, tax and cash.
| Line | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| Net margin | 4.7% | 5.9% | 7.0% | 2.9% | -8.5% | -2.6% | 1.4% | 5.2% |
| Operating margin | 12.0% | 14.4% | 15.6% | 7.7% | 0.8% | 4.5% | 10.4% | 19.1% |
| Return on equity | – | – | – | – | -17.2% | -5.5% | 3.1% | 6.1% |
| Return on capital employed | – | – | – | – | -9.2% | -0.6% | 9.1% | 12.5% |
| Return on assets | – | – | – | – | -7.9% | -2.3% | 1.4% | 3.8% |
| Debt to equity | – | – | – | – | 0.57 | 0.69 | 0.63 | 0.15 |
| Interest coverage | 2.80 | 3.60 | 6.60 | 4.40 | -2.80 | -0.10 | 1.70 | 6.00 |
| Debt to assets | – | – | – | – | 0.26 | 0.29 | 0.28 | 0.09 |
| Current ratio | – | – | – | – | 1.48 | 1.29 | 1.73 | 2.38 |
| Quick ratio | – | – | – | – | 0.82 | 0.74 | 0.97 | 1.53 |
| Cash ratio | – | – | – | – | 0.08 | 0.10 | 0.12 | 0.27 |
| Asset turnover | – | – | – | – | 0.93 | 0.89 | 0.97 | 0.74 |
| Fixed asset turnover | – | – | – | – | 4.72 | 5.51 | 6.70 | 3.01 |
| Inventory turnover | – | – | – | – | – | 2.20 | 2.10 | 1.90 |
| Receivables turnover | – | – | – | – | 4.20 | 4.10 | 4.30 | 3.30 |
| Gross margin | – | – | – | – | – | 44.5% | 47.7% | 54.3% |
| Cash from operations to profit | – | – | – | 74.0% | – | – | 381.0% | 182.0% |
| Effective tax rate | 3.4% | 12.8% | 23.6% | 15.6% | – | – | 27.2% | 35.6% |
| 11.9% |
| n/a |
| n/a |
| Yatharth Hospital & Trauma Care Services | ₹1,069.05 | ₹10,301 cr | 54.9 | 10.0% | +54.40% | +34.65% |
|---|
| Blue Jet Healthcare | ₹512.95 | ₹9,709 cr | 34.0 | 12.4% | +127.10% | −8.67% |
|---|
| Procter & Gamble Health | ₹5,595.50 | ₹9,288 cr | 24.5 | 57.7% | +17.70% | −6.69% |
|---|
| Strides Pharma Science | ₹986.10 | ₹9,089 cr | 14.7 | 18.1% | +17.10% | +2.78% |
|---|
Allotment of 135880 Shares.
Allotment of ESOP
Completion of acquisition of BioForLife Italia S.r.l
Allotment of ESOP
Update on proposed acquisition of BioForLife Italia S.r.l
ESOP Allotment
Transcript